Sangamo Therapeutics (SGMO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2024 | 03-2024 | 12-2023 | 09-2023 | 06-2023 | |
| Sales | 356 | 481 | 2,042 | 9,398 | 6,835 |
| Gross Profit | 356 | 481 | 2,042 | 9,398 | 6,835 |
| Operating Expenses | 37,440 | 52,007 | 64,101 | 115,806 | 130,407 |
| Operating Income | -37,084 | -51,526 | -62,059 | -106,408 | -123,572 |
| Other Income | 1,030 | 2,535 | 1,492 | 3,515 | 2,802 |
| Pre-tax Income | -36,054 | -48,991 | -60,567 | -102,893 | -120,770 |
| Income Tax | 74 | 98 | -272 | 1,270 | -6,264 |
| Net Income Continuous | -36,128 | -49,089 | -60,295 | -104,163 | -114,506 |
| Net Income | $-36,128 | $-49,089 | $-60,295 | $-104,163 | $-114,506 |
| EPS Basic Total Ops | -0.18 | -0.27 | -0.36 | -0.59 | -0.66 |
| EPS Basic Continuous Ops | -0.18 | -0.27 | -0.36 | -0.59 | -0.66 |
| EPS Diluted Total Ops | -0.18 | -0.27 | -0.35 | -0.59 | -0.66 |
| EPS Diluted Continuous Ops | -0.18 | -0.27 | -0.36 | -0.59 | -0.66 |
| EPS Diluted Before Non-Recurring Items | -0.17 | -0.27 | -0.34 | N/A | N/A |
| EBITDA(a) | $-34,511 | $-49,273 | $-59,348 | $-99,154 | $-66,860 |